Togninalli, Matteo http://orcid.org/0000-0001-6554-2167
Ho, Andrew T. V. http://orcid.org/0000-0002-5501-6419
Madl, Christopher M. http://orcid.org/0000-0003-3221-5041
Holbrook, Colin A.
Wang, Yu Xin http://orcid.org/0000-0001-8440-9388
Magnusson, Klas E. G.
Kirillova, Anna http://orcid.org/0000-0003-2113-5257
Chang, Andrew
Blau, Helen M. http://orcid.org/0000-0001-6503-5480
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG069858, R01 AG075436, K99 AG071738)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Li Ka Shing Foundation
Donald E. and Delia B. Baxter Foundation
Zeno Karl Schindler Swiss Study Foundation
Muscular Dystrophy Association (MDA 217821)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Life Sciences Research Foundation
Gouvernement du Canada | Canadian Institutes of Health Research (MFE-152457)
Article History
Received: 1 June 2022
Accepted: 3 January 2023
First Online: 14 January 2023
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.T.V.H. and H.M.B. are named inventors on patent applications held by Stanford University regarding PGE2 and muscle regeneration licensed to Myoforte Therapeutics. H.M.B. is a cofounder of Myoforte Therapeutics, and receives consulting fees and has equity and stock options from Myoforte Therapeutics. H.M.B. is a cofounder of Rejuvenation Technologies, Inc., and has equity and stock options in the company. C.M.M., C.A.H., Y.X.W., K.E.G.M., A.K., and A.C. declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.